Master protocols: New directions in drug discovery
Open Access
- 1 June 2020
- journal article
- research article
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 18, 100568
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and DesignAnnals of the American Thoracic Society, 2020
- Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statementBritish Journal of Cancer, 2020
- A trial like ALIC4E: why design a platform, response-adaptive, open, randomised controlled trial of antivirals for influenza-like illness?ERJ Open Research, 2018
- Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILEClinical Cancer Research, 2018
- Master Protocols to Study Multiple Therapies, Multiple Diseases, or BothNew England Journal of Medicine, 2017
- Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examplesAnnals of Oncology, 2016
- The DIAN‐TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression modelAlzheimer's & Dementia, 2016
- Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400Clinical Cancer Research, 2015
- The BATTLE Trial: Personalizing Therapy for Lung CancerCancer Discovery, 2011
- Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine KinasesClinical Cancer Research, 2008